Executive coach Joel Garfinkle shares tips to help "quiet" life science leaders assert themselves and move from invisible to ...

Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver ...

Life sciences companies can look to the automotive industry for ideas about collaborating with patients to co-create new ...

By sharing early-stage tools and data openly, life sciences companies can minimize duplication and de-risk R&D without ...

Driving growth in a family-owned pharma company requires a balance of progress and preservation, writes Merz Therapeutics CEO Stefan König.

Biotechnology is all about scientific breakthroughs that lead to transformative therapies. But despite billions invested and years of R&D, data from Deloitte found that more than half of drug launches ...

Crystalline forms of compounds and salts are frequently claimed in chemical patents, including in pharmaceuticals and agrochemicals. Different crystalline forms of the same substance — that is, ...

Amber Salzman, Ph.D., CEO at Epicrispr Biotechnologies, joined the Business of Biotech live in Boston to talk about epigenetic editing, working with the FDA, using AI for clinical endpoints, and more.

Leading a biotech company in this dynamic industry requires a strong, agile team and a championship mindset. Applying the same strategies that led my Philadelphia Eagles to the Superbowl, just as a ...

What are the key life sciences trends to watch during the second half of 2025? Evolving regulations, precision medicine, and private equity investment in oncology, according to experts at KPMG.

A key focus of Part III in this clinical trial payment series is the tax implications of trial payments. This article emphasizes that while reimbursements for out-of-pocket expenses are tax-exempt and ...

In the pharmaceutical industry, regulatory affairs (RA) and pharmacovigilance (PV) are often viewed as separate entities with distinct responsibilities. RA navigates the complex landscape of drug ...